| CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity Á Teijeira, S Garasa, M Gato, C Alfaro, I Migueliz, A Cirella, C de Andrea, ... Immunity 52 (5), 856-871. e8, 2020 | 546 | 2020 |
| Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs) C Alfaro, A Teijeira, C Oñate, G Perez, MF Sanmamed, MP Andueza, ... Clinical Cancer Research 22 (15), 3924-3936, 2016 | 394 | 2016 |
| Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury R Bertini, M Allegretti, C Bizzarri, A Moriconi, M Locati, G Zampella, ... Proceedings of the National Academy of Sciences 101 (32), 11791-11796, 2004 | 389 | 2004 |
| ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets C Bizzarri, AR Beccari, R Bertini, MR Cavicchia, S Giorgini, M Allegretti Pharmacology & therapeutics 112 (1), 139-149, 2006 | 268 | 2006 |
| Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis S Bonini, A Lambiase, P Rama, F Sinigaglia, M Allegretti, W Chao, ... Ophthalmology 125 (9), 1332-1343, 2018 | 266* | 2018 |
| Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial SC Pflugfelder, M Massaro-Giordano, VL Perez, P Hamrah, SX Deng, ... Ophthalmology 127 (1), 14-26, 2020 | 214 | 2020 |
| CXCR1/2 inhibition enhances pancreatic islet survival after transplantation A Citro, E Cantarelli, P Maffi, R Nano, R Melzi, A Mercalli, E Dugnani, ... The Journal of clinical investigation 122 (10), 3647-3651, 2012 | 174 | 2012 |
| LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells L Sturla, C Fresia, L Guida, S Bruzzone, S Scarfì, C Usai, F Fruscione, ... Journal of Biological Chemistry 284 (41), 28045-28057, 2009 | 165 | 2009 |
| Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice A Zarbock, M Allegretti, K Ley British journal of pharmacology 155 (3), 357-364, 2008 | 152 | 2008 |
| 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors M Allegretti, R Bertini, MC Cesta, C Bizzarri, R Di Bitondo, V Di Cioccio, ... Journal of medicinal chemistry 48 (13), 4312-4331, 2005 | 146 | 2005 |
| Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury DG Souza, R Bertini, AT Vieira, FQ Cunha, S Poole, M Allegretti, F Colotta, ... British journal of pharmacology 143 (1), 132-142, 2004 | 126 | 2004 |
| Treatment with DF 2162, a non‐competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice TM Cunha, MM Barsante, AT Guerrero, WA Verri Jr, SH Ferreira, ... British journal of pharmacology 154 (2), 460-470, 2008 | 114 | 2008 |
| Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2 A Moriconi, MC Cesta, MN Cervellera, A Aramini, S Coniglio, S Colagioia, ... Journal of medicinal chemistry 50 (17), 3984-4002, 2007 | 114 | 2007 |
| Targeting C5a: recent advances in drug discovery M Allegretti, A Moriconi, AR Beccari, RD Bitondo, C Bizzarri, R Bertini, ... Current medicinal chemistry 12 (2), 217-236, 2005 | 106 | 2005 |
| The role of interleukin-8 in lung inflammation and injury: implications for the management of COVID-19 and hyperinflammatory acute respiratory distress syndrome MC Cesta, M Zippoli, C Marsiglia, EM Gavioli, F Mantelli, M Allegretti, ... Frontiers in pharmacology 12, 808797, 2022 | 103 | 2022 |
| Blockade of the chemokine receptor CXCR2 ameliorates adjuvant‐induced arthritis in rats MM Barsante, TM Cunha, M Allegretti, F Cattani, F Policani, C Bizzarri, ... British journal of pharmacology 153 (5), 992-1002, 2008 | 97 | 2008 |
| CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice A Citro, A Valle, E Cantarelli, A Mercalli, S Pellegrini, D Liberati, ... Diabetes 64 (4), 1329-1340, 2015 | 96 | 2015 |
| Chemokine signaling in chemotherapy-induced neuropathic pain L Brandolini, M d’Angelo, A Antonosante, A Cimini, M Allegretti International journal of molecular sciences 20 (12), 2904, 2019 | 91 | 2019 |
| Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief A Moriconi, TM Cunha, GR Souza, AH Lopes, FQ Cunha, VL Carneiro, ... Proceedings of the National Academy of Sciences 111 (47), 16937-16942, 2014 | 83 | 2014 |
| Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non‐competitive allosteric inhibitor R Bertini, LS Barcelos, AR Beccari, B Cavalieri, A Moriconi, C Bizzarri, ... British journal of pharmacology 165 (2), 436-454, 2012 | 79 | 2012 |
